Clinical trial · Observational
NGS-based Large-panel in Targeted Drug Delivery and Immunotherapy of Lung Cancer
A Prospective Study on Companion Diagnosis by NGS-based Large-panel in Targeted Drug Delivery and Immunotherapy of Lung Cancer
NCT04159337CI-TRIAL-00041581unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Companion diagnosis by large-panel is in increasing acceptance and need during clinical cancer management. The purpose of this trial is to investigate the benefit of large-panel NGS analysis in companion diagnosis of advanced lung cancer patients and further optimize the parameters.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Neoplasms | Lung Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| The method of gene mutation detection | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Progression-free survival (PFS)
- timeFrame
- through the whole study period, an average of 3 year
- description
- PFS refers to the time from initial treatment to the time of disease progression or death
- measure
- Tumor Mutational Burden (TMB)
- timeFrame
- halfway of the study, an average of 1.5 year
- description
- TMB is defined as the total number of detected somatic mutation counts in coding regions per million bases
Secondary outcomes (3)
- measure
- Other biomarkers
- timeFrame
- halfway of the study, an average of 1.5 year
- description
- The distribution and clinical application value of molecular biomarkers such as Neoantigen, MSI and LOH in Chinese lung cancer patients
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Participant aged 18 or above, and gender unrestricted * Individual with pathologically diagnosed lung cancer Exclusion Criteria: * Patients with concomitant other tumors * Individual with severe cardiopulmonary insufficiency and hypoproteinemia * Women who were pregnant and were during their lactation
References
Publications (0)
Data not yet available
No reference posted for this study.